FDA Top Regulator Exit Hits Pharma Profits
Explore how Vinay Prasad’s resignation from FDA’s CBER amid regulatory clashes disrupts pharma profits, rare disease approvals, and vaccine strategies. Analyze impacts, compliance shifts, and future enforcement.